# Martee L. Hensley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/martee-l-hensley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,656 |
| Field | Sarcoma Diagnosis and Treatment |
| h-index | 68 |
| i10-index | 175 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5032196793 |
| ORCID iD | https://orcid.org/0009-0004-9956-1306 |
| Works | 382 |

## Researcher papers

- [Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial](https://scholariq.org/papers/efficacy-and-safety-of-trabectedin-or-dacarbazine-for-metastatic-liposarcoma-or/)
- [Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002](https://scholariq.org/papers/randomized-phase-ii-study-of-gemcitabine-and-docetaxel-compared-with-gemcitabine/)
- [Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial](https://scholariq.org/papers/gemcitabine-and-docetaxel-in-patients-with-unresectable-leiomyosarcoma-results/)
- [Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas](https://scholariq.org/papers/phase-ii-study-of-sorafenib-in-patients-with-metastatic-or-recurrent-sarcomas/)
- [Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study](https://scholariq.org/papers/fixed-dose-rate-gemcitabine-plus-docetaxel-as-second-line-therapy-for-metastatic/)
- [Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS Study](https://scholariq.org/papers/quality-of-life-in-patients-with-newly-diagnosed-chronic-phase-chronic-myeloid/)
- [Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer](https://scholariq.org/papers/clinical-utility-of-prospective-molecular-characterization-in-advanced/)

## Researcher topics

- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments-2/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.